



EXCEED

Vertex Regional CF Educational Meeting **Advancing Cystic Fibrosis total management**

5-6 October 2018

Hormuz Grand Hotel, Muscat, Oman

Excellence in **E**ducation
Empowering **D**evelopment

PRE-MEETING ASSESSMENT

You are invited to participate in a pre-assessment ahead of the CF EXCEED Regional Meeting chaired by Dr Qasem Al Salmi from the Sultanate of Oman.

The CF EXCEED Regional Meeting is an educational programme organised and funded by Vertex Pharmaceuticals (Europe) Ltd.

The purpose of the assessment is to evaluate your educational needs according to the planned content of the meeting and to track whether you feel that these needs were addressed by the meeting. This allows us to continually improve education offered by the EXCEED programme.

The assessment will take you approximately 5 minutes to complete. Your participation is required to ensure that we meet our goals; however, you are free to omit any open-ended questions you do not wish to answer. Everything you say will be treated in total confidence and will only be reported as group data with no identifying information. Vertex Pharmaceuticals (Europe) Ltd will comply with all national laws protecting your personal data and all other relevant national codes of practice.

Vertex Pharmaceuticals (Europe) Ltd is required to pass on details of adverse events/product complaints that are mentioned during the course of the assessment. Although what you say will be treated in confidence, should you raise an adverse event/product complaint in a specific patient or group of patients during the assessment, we will need to report this; even if it has already been directly reported by you to the company or the regulatory authorities. In such a situation, you will be asked whether or not you are willing to waive the confidentiality in relation to that adverse event/product complaint. Everything else you say during the course of the survey will still continue to remain confidential. If you have questions or want a copy or summary of the results, you may contact Vertex Pharmaceuticals (Europe) Ltd Medical Affairs.

I hereby:

- Confirm that I am happy to take part in this educational assessment and know that I may terminate the assessment or withhold information if I so wish.
- Understand that all data from this assessment will only be used to evaluate my educational needs in the field of cystic fibrosis and for record keeping purposes.
- Understand that anything I see or read during this assessment should be treated as confidential.
- Consent to participate in this assessment as described above

Do you agree to the above terms?

YES

NO

If you agree, please enter your personal details below and continue to the next page to start the assessment.

Full name:	
Email address:	



Learning objectives

After attending this meeting, delegates will be able to:

- a. Evaluate the differences between phenotypic and genotypic approaches in treating CF
- b. Recognize the multi-systemic clinical manifestations of CF
- c. Evaluate the pharmacological and non-pharmacological treatment options for CF lung disease in paediatric and adult patients, and the situations in which each might be appropriate.
- d. Recognize the impact of early lung damage in CF patients
- e. Discuss the benefits and challenges associated with CFTR modulator therapies
- f. Describe multidisciplinary strategies that have been shown to improve adherence to therapy and disease modification including physiotherapy, nutrition and psychological support.

Assessment questions

1. Would you be interested in attending the CF EXCEED Regional Event?

YES NO

2. Please indicate your level of agreement with the following, on a scale of 1 (strongly disagree) to 5 (strongly agree).

- a. The learning objectives for this meeting meet my current educational needs
- b. Education that meets these learning objectives could improve the care I provide to my patients
- c. Education that meets these learning objectives could benefit my colleagues

3. Please provide a description of what you hope to learn from this meeting.

4. What is your primary position?

- a. Pulmonologist/respiratory specialist
- b. Paediatrician/paediatric pulmonologist
- c. Internist/internal medicine specialist
- d. Other

5. In which country do you currently practice?

6. How many years have you been working in cystic fibrosis?

- a. 0-2
- b. 3-5
- c. 6-10
- d. 11+

7. For the following aspects of CF management, indicate your level of agreement using the scale from 1 (strongly disagree) to 5 (strongly agree):

- a. I know the difference between phenotypic and genotypic approaches to treatment
- b. I know which measurements can be used to evaluate signs of early lung damage and treatment efficacy
- c. I know how to ensure high levels of adherence to a variety of CF treatments
- d. I know how to evaluate and treat pulmonary exacerbations
- e. I know the importance of the multidisciplinary strategies and how they impact CF patient care
- f. I know how to identify which of my patients are eligible for CFTR modulator therapies